Literature DB >> 8790196

Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors.

T Inoue1, E E Kim, F C Wong, D J Yang, P Bassa, W H Wong, M Korkmaz, W Tansey, K Hicks, D A Podoloff.   

Abstract

UNLABELLED: Two commonly used tumor-seeking agents for PET are 2-deoxy-2-18F-fluoro-D-glucose (FDG) and L-methyl-11C-methionine (Met). This study compared FDG and Met in detecting residual or recurrent malignant tumors in the same patients.
METHODS: Thirty-four lesions in 24 patients with clinically suspected recurrent or residual tumors were studied with PET using Met as well as FDG. FDG scans were conducted 1 hr after the completion of PET with Met. The color-coded superimposed images of standardized uptake values (SUVs) and transmission data were produced, and the peak SUVs in the lesions were then evaluated. Lesions above 2.5 SUV were interpreted as positive results for active tumor.
RESULTS: The sensitivity of FDG-PET and Met-PET were 64.5% (20/31 lesions) and 61.3% (19/31 lesions), respectively. The mean SUV of FDG in residual or recurrent malignant tumors (n = 31) was significantly higher than that of Met but there was a significant correlation (r = 0.788, p < 0.01) between FDG and Met SUVs in all lesions (n = 34).
CONCLUSION: PET using FDG and Met appear equally effective in detecting residual or recurrent malignant tumors although FDG uptakes were slightly higher than Met uptakes. Both showed a limited diagnostic sensitivity for small (< 1.5 cm) tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8790196

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  11 in total

Review 1.  Clinical applications of molecular imaging in sarcoma evaluation.

Authors:  Rodney J Hicks; Guy C Toner; Peter F M Choong
Journal:  Cancer Imaging       Date:  2005-06-21       Impact factor: 3.909

Review 2.  Metabolic positron emission tomography imaging in cancer detection and therapy response.

Authors:  Aizhi Zhu; Daniel Lee; Hyunsuk Shim
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

3.  System a amino acid transport-targeted brain and systemic tumor PET imaging agents 2-amino-3-[(18)F]fluoro-2-methylpropanoic acid and 3-[(18)F]fluoro-2-methyl-2-(methylamino)propanoic acid.

Authors:  Weiping Yu; Jonathan McConathy; Jeffrey J Olson; Mark M Goodman
Journal:  Nucl Med Biol       Date:  2014-08-01       Impact factor: 2.408

4.  Evaluation of the biodistribution of 11C-methionine in children and young adults.

Authors:  Sebastian M Harris; James C Davis; Scott E Snyder; Elizabeth R Butch; Amy L Vavere; Mehmet Kocak; Barry L Shulkin
Journal:  J Nucl Med       Date:  2013-09-19       Impact factor: 10.057

Review 5.  PET/CT in primary musculoskeletal tumours: a step forward.

Authors:  A Lakkaraju; C N Patel; K M Bradley; A F Scarsbrook
Journal:  Eur Radiol       Date:  2010-06-25       Impact factor: 5.315

6.  Metabolism of radiolabeled methionine in hepatocellular carcinoma.

Authors:  Yu Kuang; Fangjing Wang; David J Corn; Haibin Tian; Zhenghong Lee
Journal:  Mol Imaging Biol       Date:  2014-02       Impact factor: 3.488

Review 7.  Current molecular imaging positron emitting radiotracers in oncology.

Authors:  Aizhi Zhu; Hyunsuk Shim
Journal:  Nucl Med Mol Imaging       Date:  2011-02-01

8.  Quantitative hormone therapy follow-up in an ER+/ERαKD mouse tumor model using FDG and [11C]-methionine PET imaging.

Authors:  Michel Paquette; Sébastien Tremblay; Francois Bénard; Roger Lecomte
Journal:  EJNMMI Res       Date:  2012-11-09       Impact factor: 3.138

Review 9.  Methodology for quantitative rapid multi-tracer PET tumor characterizations.

Authors:  Dan J Kadrmas; John M Hoffman
Journal:  Theranostics       Date:  2013-10-04       Impact factor: 11.556

10.  Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer.

Authors:  Azita Monazzam; Raymond Josephsson; Carl Blomqvist; Jörgen Carlsson; Bengt Långström; Mats Bergström
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.